Skip to main content
. 2020 Aug 7;10:1245. doi: 10.3389/fonc.2020.01245

Figure 2.

Figure 2

Association of mRNA expression of HLA-DPB2 and HLA-DPB1 with clinicopathological characteristics in BC patients using bc-GenExMiner database. (A1,A2) Association of HLA-DPB2 and HLA-DPB1 expression with estrogen receptor status; (B1,B2) Association of HLA-DPB2 and HLA-DPB1 expression with progesterone receptor status; (C1,C2) Association of HLA-DPB2 and HLA-DPB1 expression with human epidermal growth factor receptor-2 (HER2) status; (D1,D2) Association of HLA-DPB2 and HLA-DPB1 expression with P53 status; (E1,E2) Association of HLA-DPB2 and HLA-DPB1 expression with SBR grade; (F1,F2) Association of HLA-DPB2 and HLA-DPB1 expression with basal-like status; (G1,G2) Association of HLA-DPB2 and HLA-DPB1 expression with triple negative and basal-like status; (H1,H2) Association of HLA-DPB2 and HLA-DPB1 expression with PAM50 subtypes. Difference of mRNA expression was compared by Welch's tests and Dunnett-Tukey-Kramer's test. BC, breast cancer; *P < 0.05, ***P < 0.001.